Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease

AIDS

Volumn 13, Issue 10, 1999, Pages 1187-1193

  Mezzaroma, Ivano ^a   Carlesimo, Maurizio ^a   Pinter, Elena ^a   Alario, Cecilia ^a   Sacco, Giovanna ^a   Muratori, Donatella Santini ^a   Bernardi, Maria Livia ^a   Paganelli, Roberto ^a   Aiuti, Fernando ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

HAART; HIV; Immunocompromised patients; Lymphoproliferative responses; Memory CD4 T cells; Mitogen; Naive CD4 T cells; Recall antigen

Indexed keywords

ANTIGEN; ANTIRETROVIRUS AGENT; CANDIDA ANTIGEN; CD4 ANTIGEN; GLYCOPROTEIN; INDINAVIR; MITOGENIC AGENT; RITONAVIR; TETANUS TOXOID; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; MEMORY CELL; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD; WEIGHT GAIN;

ADULT; ANTI-HIV AGENTS; ANTIGEN PRESENTATION; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOLOGIC MEMORY; INDINAVIR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 0032771054     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199907090-00006     Document Type: Article

References (28)

1. 1. Giorgi JV, Detels R. T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS Cohort study. Clin Immunol Immunopathol 1989, 52:10-18.
2. 2. Clerici M, Stocks NI, Zajac RA, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. J Clin Invest 1989, 84:1892-1899.
3. 3. Hammer SM, Squires KF, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
4. 4. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
5. 5. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
6. 6. Emery S, Lane HC. Immune reconstitution in HIV infection. Curr Opin Immunol 1997, 9:568-572.
7. 7. Li TS, Lubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998, 351:1682-1686.
8. 8. Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med 1997, 3:533-540.
9. 9. Gray CM, Schapiro JM, Winters MA, Merigan TC. Changes in CD4+ and CD8+ T cell subset in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. AIDS Res Hum Retroviruses 1998, 14:561-569.
10. 10. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1993, 41:1-19.
11. 11. Pontesilli O, Guerra EC, Ammassari A, et al. Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team. AIDS 1998, 12:473-480.
12. 12. Quinti I, Palma C, Guerra EC et al. Proliferative and cytotoxic responses to mannoproteins of Candida albicans by peripheral blood lymphocytes of HIV-infected patients. Clin Exp Immunol 1991, 85:485-492.
13. 13. Schrier RD, Gnann JW, Landes R, et al. T cell recognition of HIV synthetic peptides in a natural infection. J Immunol 1989, 142:1166-1176.
14. 14. Pakker NG. Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation. Nature Med 1998, 4:200-214.
15. 15. Mosier D. HIV results in the frame. CD4+ cell turnover. Nature 1995, 375:193-194.
16. 16. Sprent J, Tough D. HIV results in the frame. CD4+ cell turnover. Nature 1995, 375:194.
17. 17. Roederer M. Getting to the HAART of T cell dynamics. Nature Med 1998, 4:145-146.
18. 18. Margolick JB, Munoz A, Donnenberg AD, et al. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. The Multicenter AIDS Cohort Study. Nature Med 1995, 1:674-680.
19. 19. Walker RE, Carter CS, Muul L, et al. Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults. Nature Med 1998, 4:852-856.
20. 20. Hellerstein M, Hanley MB, Cesar D, et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1 infected humans. Nature Med 1999; 5:83-89.
21. 21. Gorochow G, Neuman AU, Kereveur A, et al. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nature Med 1998, 4:215-221.
22. th World AIDS Conference. Geneva, June 1998 [abstract 42184].
23. 23. Levy JA. Caution: should we be treating HIV infection early? Lancet 1998, 352:982-983.
24. 24. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995, 122:573-579.
25. 25. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954.
26. th World AIDS Conference. Geneva, June 1998 [abstract 31134].
27. 27. Carlesimo M, Pontesilli O, Guerra EC, et al. Long-term evaluation of cellular immunity during antiretroviral therapy and immunization with human immunodeficiency virus type 1 (HIV-1) env glycoprotein in HIV-1-infected persons. J Infect Dis 1997, 176:904-912.
28. TM) on β chemokine and cytokine production in subjects with HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:343-350.